Drugs & Targets FDA grants accelerated approval to encorafenib with cetuximab and mFOLFOX6 for metastatic colorectal cancer with a BRAF V600E mutation January 10, 2025Vol.51 No.01
Drugs & Targets FDA clears IND application for Recursion’s LSD1 inhibitor REC-4539 January 10, 2025Vol.51 No.01
Capitol Hill Don’t confirm RFK Jr. for HHS, 77 Nobel laureates urge the Senate December 13, 2024Vol.50 No.46By Yiqing Wang
Drugs & Targets FDA grants accelerated approval to zenocutuzumab-zbco for NSCLC and pancreatic adenocarcinoma December 06, 2024Vol.50 No.45
Clinical Roundup NCCN updates CML treatment guidelines following FDA approval of Scemblix for newly diagnosed patients November 22, 2024Vol.50 No.44
Drugs & Targets FDA approves new alternative standard related to mammography report assessments November 22, 2024Vol.50 No.44
Drugs & Targets FDA approves revumenib for r/r acute leukemia with a KMT2A translocation November 22, 2024Vol.50 No.44
